USANA Health Sciences (NYSE:USNA) Director Sells $34,632.50 in Stock

USANA Health Sciences, Inc. (NYSE:USNA) Director John Turman Fleming sold 1,750 shares of the business’s stock in a transaction that occurred on Friday, October 31st. The stock was sold at an average price of $19.79, for a total transaction of $34,632.50. Following the completion of the sale, the director directly owned 4,565 shares of the company’s stock, valued at $90,341.35. This represents a 27.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

USANA Health Sciences Stock Up 2.1%

USNA stock traded up $0.44 during trading hours on Monday, hitting $21.59. The company’s stock had a trading volume of 97,972 shares, compared to its average volume of 191,810. The stock has a 50 day moving average price of $26.78 and a two-hundred day moving average price of $28.84. The company has a market capitalization of $394.40 million, a PE ratio of 24.42, a price-to-earnings-growth ratio of 0.94 and a beta of 0.61. USANA Health Sciences, Inc. has a 12 month low of $18.69 and a 12 month high of $41.83.

USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings data on Thursday, October 9th. The company reported $0.56 earnings per share (EPS) for the quarter. The business had revenue of $200.22 million during the quarter. USANA Health Sciences had a net margin of 1.86% and a return on equity of 6.96%. USANA Health Sciences has set its Q3 2025 guidance at -0.150–0.150 EPS. Sell-side analysts expect that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

USNA has been the subject of several research analyst reports. Wall Street Zen cut shares of USANA Health Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. Zacks Research cut shares of USANA Health Sciences from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 21st. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of USANA Health Sciences in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, USANA Health Sciences currently has an average rating of “Reduce” and a consensus target price of $36.00.

Hedge Funds Weigh In On USANA Health Sciences

Hedge funds have recently made changes to their positions in the business. PNC Financial Services Group Inc. raised its stake in shares of USANA Health Sciences by 339.6% in the 1st quarter. PNC Financial Services Group Inc. now owns 998 shares of the company’s stock valued at $27,000 after buying an additional 771 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in shares of USANA Health Sciences by 382.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company’s stock valued at $73,000 after buying an additional 1,901 shares in the last quarter. CWM LLC raised its stake in shares of USANA Health Sciences by 109.7% in the 2nd quarter. CWM LLC now owns 2,762 shares of the company’s stock valued at $84,000 after buying an additional 1,445 shares in the last quarter. AlphaQuest LLC increased its position in shares of USANA Health Sciences by 300.9% during the 1st quarter. AlphaQuest LLC now owns 3,412 shares of the company’s stock worth $92,000 after purchasing an additional 2,561 shares in the last quarter. Finally, Quantbot Technologies LP increased its position in shares of USANA Health Sciences by 19.5% during the 2nd quarter. Quantbot Technologies LP now owns 3,957 shares of the company’s stock worth $121,000 after purchasing an additional 646 shares in the last quarter. Institutional investors and hedge funds own 54.25% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.